Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation

The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate–based or abacavir (ABC)-based re...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Acquir Immune Defic Syndr
Auteurs principaux: Perez-Valero, Ignacio, Llibre, Josep M., Castagna, Antonella, Pulido, Federico, Molina, Jean-Michel, Esser, Stefan, Margot, Nicolas, Shao, Yongwu, Temme, Lauren, Piontkowsky, David, McNicholl, Ian R., Haubrich, Richard
Format: Artigo
Langue:Inglês
Publié: JAIDS Journal of Acquired Immune Deficiency Syndromes 2021
Sujets:
Clinical Science
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7899215/
https://ncbi.nlm.nih.gov/pubmed/33315694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000002595
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires